TCL1 Predicts Time to Treatment in Chronic Lymphocytic Leukemia

被引：0
|
作者：
Ng, D. P.
Bennett, R. R.
Lansigan, F.
Levy, N. B.
Danilov, A. V.
Kaur, P.
机构：
[1] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[2] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1501
引用
收藏
页码：357A / 357A
页数：1
相关论文
共 50 条
  • [41] Expression of ZAP-70 Does Not Accelerate Leukemia Development and Progression in the Eμ-TCL1 Transgenic Mouse Model of Chronic Lymphocytic Leukemia
    Gobessi, Stefania
    Belfiore, Francesca
    Bennardo, Sara
    Doe, Brendan
    Laurenti, Luca
    Efremov, Dimitar G.
    BLOOD, 2012, 120 (21)
  • [42] Hyper-Activation of the Adenosinergic Axis in the Eμ-TCL1 Chronic Lymphocytic Leukemia Mouse Model Offers Therapeutic Opportunities
    Vaisitti, Tiziana
    Serra, Sara
    Bologna, Cinzia
    Vitale, Nicoletta
    Gobessi, Stefania
    Efremov, Dimitar G.
    Deaglio, Silvia
    BLOOD, 2017, 130
  • [43] CLL CELLS INDUCE CLONAL T CELL SKEWING AND SUBSETSHIFTING IN THE MURINE TCL1 TRANSGENIC CHRONIC LYMPHOCYTIC LEUKEMIA MODEL
    Egle, A.
    Pinon-Hofbauer, J.
    Heyder, C.
    Denk, U.
    Kocher, T.
    Holler, C.
    Trapin, D.
    Asslaber, D.
    Tinhofer, I.
    Greil, R.
    ANNALS OF ONCOLOGY, 2011, 22 : 144 - 144
  • [44] Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL)
    Palamarchuk, Alexey
    Yan, Pearlly S.
    Zanesi, Nicola
    Wang, Linan
    Rodrigues, Benjamin
    Murphy, Mark
    Balatti, Veronica
    Bottoni, Arianna
    Nazaryan, Natalya
    Alder, Hansjuerg
    Rassenti, Laura
    Kipps, Thomas J.
    Freitas, Michael
    Croce, Carlo M.
    Pekarsky, Yuri
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (07) : 2555 - 2560
  • [45] IDO1-Targeted Therapy Does Not Control Disease Development in the Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
    Ozturk, Selcen
    Kalter, Verena
    Roessner, Philipp M.
    Sunbul, Murat
    Seiffert, Martina
    CANCERS, 2021, 13 (08)
  • [46] Comparison of TCL1 Overexpression and TCL1 Gene Rearrangement in Patients with T-Cell Prolymphocytic Leukemia
    Sun, Yi
    Tang, Guilin
    Hu, Zhihong
    Medeiros, L. J.
    Wang, Sa
    MODERN PATHOLOGY, 2017, 30 : 379A - 380A
  • [47] High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia
    Herling, Marco
    Patel, Kaushali A.
    Weit, Nicole
    Lilienthal, Nils
    Hallek, Michael
    Keating, Michael J.
    Jones, Dan
    BLOOD, 2009, 114 (21) : 4675 - 4686
  • [48] Comparison of TCL1 Overexpression and TCL1 Gene Rearrangement in Patients with T-Cell Prolymphocytic Leukemia
    Sun, Yi
    Tang, Guilin
    Hu, Zhihong
    Medeiros, L. J.
    Wang, Sa
    LABORATORY INVESTIGATION, 2017, 97 : 379A - 380A
  • [49] Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia
    Janovska, Pavlina
    Verner, Jan
    Kohoutek, Jiri
    Bryjoval, Lenka
    Dzimkova, Marta
    Skabrahova, Hana
    Radaszkiewicz, Tomasz
    Nemcova, Tereza
    Hoferova, Zuzana
    Vasickova, Katerina
    Smyckova, Lucie
    Gregorova, Michaela
    Egle, Alexander
    Pavlova, Sarka
    Poppova, Lucie
    Pospisilova, Sarka
    Bryja, Viterslav
    LEUKEMIA & LYMPHOMA, 2017, 58 : 210 - 211
  • [50] TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
    Bresin, A.
    D'Abundo, L.
    Narducci, M. G.
    Fiorenza, M. T.
    Croce, C. M.
    Negrini, M.
    Russo, G.
    CELL DEATH & DISEASE, 2016, 7 : e2071 - e2071
12345